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Stem/progenitor cells from multiple tissues have been isolated based on enhanced activity of cytosolic aldehyde dehydrogenase
(ALDH) enzyme. ALDH activity has emerged as a reliable marker for stem/progenitor cells, such that ALDHbright/high cells from
multiple tissues have been shown to possess enhanced stemness properties (self-renewal and multipotency). So far though, not
much is known about ALDH activity in specific fetal organs. In this study, we sought to analyze the presence and activity of
the ALDH enzyme in the stem cell antigen-1-positive (Sca-1+) cells of fetal human heart. Biochemical assays showed that a
subpopulation of Sca-1+ cells (15%) possess significantly high ALDH1 activity. This subpopulation showed increased expression of
self-renewal markers compared to the ALDHlow fraction. The ALDHhigh fraction also exhibited significant increase in proliferation
and pro-survival gene expression. In addition, only the ALDHhigh and not the ALDHlow fraction could give rise to all the cell types
of the original population, demonstrating multipotency. ALDHhigh cells showed increased resistance against aldehyde challenge
compared to ALDHlow cells. These results indicate that ALDHhigh subpopulation of the cultured human fetal cells has enhanced
self-renewal, multipotency, high proliferation, and survival, indicating that this might represent a primitive stem cell population
within the fetal human heart.

1. Introduction
Stem cell antigen-1-positive (Sca-1+) cells from adult mouse
hearts were shown to demonstrate increased proliferation
and stemness along with potential to differentiate into multiple cardiac cell lineages [1–3]. Smits et al. have successfully
isolated Sca-1+ cells from adult human heart and further
demonstrated their ability to differentiate into cardiomyocytes [4]. These studies unequivocally suggest that Sca-1+
cells isolated from cardiac tissue are a subset of cardiac progenitor cells. Over the years, several approaches and strategies

have been developed to enhance regeneration capacity of
stem/progenitor cells by improving means of identification,
expansion, pluripotency, self-renewal, and survival of these
cells [5]. For instance, circulating progenitor cells, umbilical
cord blood cells (UCBCs), hematopoietic stem cells (HSCs),
and tissue-specific stem/progenitor cells are being identified
based on aldehyde dehydrogenase (ALDH) activity [6–12].
Instead of solely relying on presence of cell surface markers,
which may sometimes vary upon experimental processing during cell isolation, the functional cytosolic ALDH
(ALDH1) activity assay is becoming more reliable and widely
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used [7, 13]. ALDHhigh cells from multiple tissues have been
shown to possess enhanced stemness properties, specifically
self-renewal and differentiation [7, 11, 13]. ALDHhigh stem
cells are a small population of cells (0.5–5%) highly enriched
for pluripotency [14–16]. In fact ALDHhigh stem cells isolated
from the blood are in clinical trials for ischemic heart failure
[17]. Therefore in this study, we hypothesized that among
the Sca-1+ cells from the human fetal heart, ALDHhigh cells
exhibit high self-renewal capacity, stemness, survival, and
proliferation capacity compared to ALDHlow cells.

2. Materials and Methods
2.1. Isolation and Expansion of Fetal Sca-1+ Cells. To isolate
fetal human Sca-1+ cells, anti-mouse Sca-1 antibody based
magnetic separation was used, as described in a previous
protocol [4]. The study protocol used here was approved by
the Stanford Institutional Review Board. In brief, human fetal
hearts (StemExpress, Diamond Springs, CA) were perfused
using a Lagendorff apparatus, using Tyrode solution containing collagenase. Following this, fetal Sca-1+ cells were isolated
by magnetic cell sorting (MACS, Miltenyi Biotec, Sunnyvale,
CA), using Sca-1-coupled magnetic beads, according to the
manufacturer’s protocol. Sca-1+ cells were eluted from the
column by washing with PBS supplemented with 0.5%
bovine serum albumin and 2 mM EDTA. The eluted Sca-1+
cells were cultured on 0.1% gelatin-coated dishes in M199
(Gibco)/EGM-2 (3 : 1) media, supplemented with 10% FBS
(Gibco), 10 ng/mL basic fibroblast growth factor (bFGF),
5 ng/mL epithelial growth factor (EGF), 5 ng/mL insulin-like
growth factor (IGF-1), 5 ng/mL vascular endothelial growth
factor (VEGF), 5 ng/mL heparin, 5 ng/mL ascorbic acid,
nonessential amino acids, 𝛽-mercaptoethanol, 1x Penicillin,
and 1x streptomycin. All Sca-1+ cells used for this study were
between passages 2 and 5.
2.2. Western Blotting. Protein samples (30 𝜇g) were separated on SDS-polyacrylamide gels by electrophoresis and the
proteins were transferred to immobilon-P membranes (GE
Healthcare). Level of the ALDH1 protein was determined
using anti-ALDH1A1 antibodies (Abcam) at a concentration
of 1 : 1000. Anti-enolase antibody (Santa Cruz Biotechnology,
Santa Cruz) was used as housekeeping marker at a concentration of 1 : 1000. The bound antibodies were visualized with
horseradish peroxidase- (HRP-) coupled secondary antibody
and chemiluminiscence detection system.
2.3. ALDH Activity Assay by Spectrophotometer. ALDH1
activity was measured in unsorted control and ALDH specific inhibitor, diethylaminobenzaldehyde- (DEAB-) treated
cells by following the procedure as described elsewhere [6].
In brief, enzymatic activity of ALDH1 in cell lysate was
determined spectrophotometrically by reductive reaction of
NAD+ to NADH at 340 nm (Beckman).
10 mM phenyl acetaldehyde was used as the substrate
for ALDH1. All the assays were carried out at 25∘ C in 0.1 M
sodium pyrophosphate buffer, pH = 9.5. 2.4 mM NAD+.
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2.4. Flow Cytometry Based Sorting of ALDHℎ𝑖𝑔ℎ and ALDH𝑙𝑜𝑤
Sca-1+ Cells. Sca-1+ cells were sorted by flow cytometry into
subpopulations having high or low ALDH enzyme activity
using the Aldefluor kit (Stem Cell Technologies, Vancouver,
Canada), as per manufacturer’s instructions. Briefly, cultured
human fetal Sca-1+ cells were resuspended in Aldefluor assay
buffer, and 1 × 106 cells/mL cell suspension was added to
a tube containing 5 𝜇L of the ALDH substrate, Aldefluor.
0.5 mL of this suspension was transferred to a second tube,
containing the DEAB, which serves as a negative control.
Following 30-minute incubation at 37∘ C and centrifugation,
the cells were washed with the assay buffer, followed by
resuspension in 0.3 mL of ice cold Aldefluor assay buffer for
flow sorting (carried out on BD FACS Aria). Viability of the
cells was determined by 7-amino actinomycin D (7-AAD).
The DEAB negative control was used to set the gate. Cells
having the highest fluorescence at 515 nm were collected as
the ALDHhigh population. The nonfluorescent population at
515 nm was collected as the ALDHlow cells. After sorting,
the ALDHhigh and ALDHlow Sca-1+ cells were cultured
under identical culture conditions. After one week in culture,
Aldefluor assay was carried out on the two populations as
described above, followed by flow cytometric analysis of
ALDH activity.
2.5. Quantitative (Real-Time) Reverse Transcriptase (RT) PCR
(qRT-PCR). Equal number of ALDHhigh and ALDHlow cells
at passage 2 was seeded in a 6-well plate and was harvested at
70–80% confluency. The cell pellet obtained after centrifugation was used for RNA isolation. Total RNA was purified from
the ALDHhigh and ALDHlow Sca-1+ cells using RNeasy Mini
kit (Qiagen). 1 𝜇g of total RNA was reverse transcribed using
high capacity cDNA transcription kit (Applied Biosystems),
followed by high throughput quantitative gene expression
analysis using Taqman probes for all the genes analyzed. To
assess the status of stemness markers, the following Taqman
probes were used: Oct4 (Hs00982625 m1) for organic cation
transporter-4 gene, Nanog (Hs02387400 g1) for the gene of
nanog homeobox, GATA4 (Hs00171403 m1) for GATA binding protein 4 gene, Isl1 (Hs00158126 m1) for ISL1 transcription factor gene, and MEF2C (Hs00231149 m1) for myocyte
enhancer factor 2C gene. Expression of two genes, the
nuclear antigen Ki67 (Hs01032443 m1) and the antiapoptotic
factor, B-cell CLL/lymphoma (Bcl) 2 (Hs00608023 m1) were
assessed for comparative analysis of proliferation and cell
death, respectively. The assay was carried out on the StepOne
Plus Real-Time PCR platform (Applied Biosystems). 18S was
used as the internal control gene for all samples and the
ΔΔCt method was used to calculate fold change of gene
expression.
2.6. Cell Death Assay after Aldehydic Challenge. First
ALDHhigh and ALDHlow Sca-1+ cells were treated with 50 𝜇M
acetaldehyde for 4 hr. Acetaldehyde-induced apoptotic cell
death was determined using annexin V staining via flow
cytometry following manufacturer’s instructions (Roche).
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Figure 1: Level and activity of ALDH1. (a) Western immunoblot bands of ALDH1 and enolase, the loading control for cytosolic proteins,
and (b) measurement of ALDH activity with phenyl acetaldehyde as substrate from total cell lysates (below) of control (open bar) and DEAB
(1.5 𝜇M) treated (filled bar) cells. ∗∗ 𝑃 value < 0.006.

2.7. Statistical Analysis. All experiments were done in triplicate. FACS and real-time PCR data were analyzed using
Graphpad Prism (GraphPad Software, Inc., CA, USA). All
data have been presented as mean ± standard error over
mean (SEM). For analysis of the FACS data, 1-way ANOVA,
followed by Kruskal-Wallis test was used to calculate significance of the differences. For analysis of the RT-PCR
data, unpaired 𝑡-test was used to compare significance of
differences between ALDHhigh and ALDHlow cells for each
individual gene. In all cases, differences were considered
significant at 𝑃 values <0.05.

3. Results
3.1. ALDH1 Level and Activity in Cultured Sca-1+ Human
Fetal Cells. Prior to isolating ALDHhigh cells using Aldefluor
kit, which is based on ALDH1 activity, we first determined
ALDH1 presence/level in cultured human fetal cells by
Western blot analysis. The results showed that these cells
do express ALDH1A1 (Figure 1(a)). We also found significant ALDH1 activity in human fetal cell lysates by spectrophotometric assay using phenyl acetaldehyde as substrate
(Figure 1(b)). In this activity assay, conversion of phenyl
acetaldehyde into phenyl acetic acid by ALDH, generating
NADH was measured spectrophotometrically at 340 nm. We
found that DEAB (1.5 𝜇M for 1 hour at 37∘ C) significantly
decreased ALDH1 activity.
3.2. Identification and Isolation of ALDHℎ𝑖𝑔ℎ Cells. We went
ahead to identify and isolate the Sca-1+ human fetal cells subpopulation with the highest level of ALDH1 activity using the
fluorescence based Aldefluor assay, which has been routinely
utilized to identify and isolate primitive hematopoietic stem
cells [7]. Using this assay, coupled with flow cytometry, we
identified a subpopulation of ∼15% cells within the Sca-1+
cells which demonstrated ALDHhigh phenotype (Figure 2).

Close to 98% of cells were viable with this procedure as
determined by 7-AAD staining (data not shown). Both the
ALDHhigh and ALDHlow cells were sorted and expanded for
downstream characterization.
3.3. ALDHℎ𝑖𝑔ℎ Sca-1+ Cells Are Enriched in Stemness and
Cardiac Development-Specific Genes. Equal number of first
passage ALDHhigh and ALDHlow Sca-1+ cells were seeded
under identical culture conditions and harvested for realtime PCR after 48–72 hrs. ALDHhigh cells demonstrated
relatively high levels of stem cell-specific markers such as
Oct4 and Nanog as compared to ALDHlow Sca-1+ cells
(𝑃 < 0.05) (Figure 3). In addition, multiple early mesodermspecific transcripts, such as GATA4, Isl1 and MEF2C, were
also enriched in ALDHhigh Sca-1+ cells compared to ALDHlow
Sca-1+ cells (𝑃 value < 0.05) (Figure 3).
3.4. Increase in Proliferation and Survival Potency in
ALDHℎ𝑖𝑔ℎ Sca-1+ Cells. We also observed a difference
in survival and proliferation status between the two
populations, immediately after sorting and seeding them.
The ALDHlow Sca-1+ cells had a large proportion of floating,
dead cells when compared to the ALDHhigh Sca-1+ cells.
In order to confirm this, equal number of ALDHhigh
and ALDHlow Sca-1+ cells were seeded and harvested
after 48 hours, followed by assessment for expression of a
proliferation-specific gene, Ki67 and an antiapoptotic marker,
Bcl2. The ALDHhigh Sca-1+ cells demonstrated significant
upregulation of both these markers when compared to the
ALDHlow Sca-1+ cells (𝑃 value < 0.05) (Figure 4), indicating
enhanced proliferation as well as survival advantage of
ALDHhigh Sca-1+ cells.
The apoptotic cell death was lower in ALDHhigh Sca-1+
cells compared to ALDHlow Sca-1+ cells in both basal condition and acetaldehyde treatment as shown in Table 1.
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Figure 2: Identification of ALDHhigh subpopulation in cultured fetal Sca-1+ cells using activity based flow cytometric sorting. There is a
distinct and consistent ALDHhigh Sca-1+ cell population (10–15%) in fetal heart. Dot plots have been shown for three human fetal Sca-1+ cell
samples. Left panel represents negative control for each sample. Right panel is the test sample in the absence of the inhibitor, DEAB. ALDH
activity is measured in the FITC channel, represented along 𝑥-axis; forward scatter (FSC) is on the 𝑦-axis.
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Table 1: Reduced apoptotic death in ALDHhigh cells with acetaldehyde treatment.
Basal

Cell type

ALDHhigh cells
102 ± 12

% apoptotic death

ALDHlow cells
197 ± 2∗

Acetaldehyde-treated
ALDHhigh cells
ALDHlow cells
163 ± 32
338 ± 5∗∗##

∗

𝑃 value < 0.001 versus ALDHhigh cells in basal conditions; ∗∗ 𝑃 value < 0.005 versus ALDHhigh cells with acetaldehyde treatment; ## 𝑃 value < 0.0001 versus
ALDHlow cells in basal conditions. 𝑁: 4 repeats.
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Figure 3: Real-time PCR analysis of ALDHhigh and ALDHlow
Sca-1+ cells. Increased expression of markers for stem cells, early
cardiac, and self-renewal exclusively in ALDHhigh cells compared to
ALDHlow Sca-1+ cells. (𝑛 = 4; ∗ 𝑃 value < 0.05).
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After two weeks in culture, both populations were subject to
the Aldefluor assay to determine ALDH activity. While the
ALDHlow Sca-1+ cells could only give rise to ALDHlow subpopulation (>97%; 𝑃 value < 0.05) (Figure 5), the ALDHhigh
Sca-1+ cells recapitulated the original population by giving
rise to both the ALDHhigh and ALDHlow populations, in
addition to maintaining a high percentage of the cells with
ALDHhigh phenotype. This was consistently observed for
multiple samples, and this observation held true even after
2-3 weeks of culture.

Bcl2
Genes

ALDHhigh
ALDHlow

Figure 4: Gene expression analysis of proliferation and prosurvival
genes in ALDHhigh and ALDHlow Sca-1+ cells. Quantitative realtime PCR based gene expression analysis of a proliferation-specific
gene (Ki67) and antiapoptotic gene, Bcl2 to compare ALDHhigh and
ALDHlow Sca-1+ cells. Fold change in gene expression is with respect
to ALDHlow Sca-1+ cells. (𝑛 = 3; ∗ 𝑃 value < 0.05).

3.5. ALDHℎ𝑖𝑔ℎ Sca-1+ Cells Produce Increased Number of
ALDHℎ𝑖𝑔ℎ Sca-1+ Cells upon Culture. In order to test the
potential of ALDHhigh and ALDHlow Sca-1+ cells to give rise
to all the cell types existing in the original population from
which they were derived, the two populations were cultured.

This is the first study which identifies a distinct subpopulation
of cells in the fetal human heart having high ALDH activity
and possessing enhanced potency for self-renewal, proliferation, survival and multipotency.
ALDH has been shown to be a functional marker of
stem cells in multiple tissues and tumors of multiple organs
[8–11]. The earliest studies of identification and isolation of
live ALDHhigh cells using a fluorescence based assay were
carried out in cord blood cells [7] and gradually expanded to
other types of stem cells [12–14]. In this in vivo cellular assay,
BODIPY-aminoacetaldehyde (BAAA) is converted by intracellular isoform of ALDH, ALDH1 into a negatively charged
reaction product, BODIPY-aminoacetate (BAA) which is
retained inside cells, causing the cells expressing high levels
of ALDH to become brightly fluorescent. Now this method,
known as the “Aldefluor assay” is used routinely to enrich
ALDHhigh stem/progenitor cells from multiple tissues and
tumor samples [9].
We confirmed biochemically that ALDH1 was expressed
in human fetal Sca-1+ cells using immunoblotting technique
and significant ALDH1 activity was found by enzymatic activity assay when phenyl acetaldehyde was used as a substrate
(Figure 1). After confirming that human fetal Sca-1+ cells
contain ALDH1, we used flow cytometry based Aldefluor
assay to identify and sort the ALDHhigh subpopulation. This
fraction comprised ∼15% of the human fetal heart cells
(Figure 2). This is higher than the ALDHhigh percentage
reported from other tissues [15–17], that is, 0.5–5%. This
increase in ALDHhigh population may be because of fetal
origin. Increase in numbers of cardiac progenitors in neonatal
heart compared to adult heart has been reported in earlier
studies [18, 19]. Further studies could demonstrate whether
this is true for ALDHhigh Sca-1+ cells too.
In addition to upregulation of typical stem cell markers
(Oct4 and Nanog) in the ALDHhigh Sca-1+ cells with respect
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Figure 5: Analysis of the potential of ALDHhigh and ALDHlow Sca-1+ cells to recapitulate the original population. (a) Representation of flow
cytometric analysis of ALDHhigh Sca-1+ cells (left panel) and ALDHlow Sca-1+ cells (right panel) one week after in vitro culture. (b) Graphical
representation of the percentage of ALDHhigh Sca-1+ cells in the original population, arising from ALDHhigh Sca-1+ cells and ALDHlow Sca-1+
cells. (𝑛 = 3; ∗ 𝑃 value < 0.001).
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to ALDHlow Sca-1+ cells, the Isl1 transcript, which is a wellestablished marker during cardiogenesis in the fetus, was
seen to be enriched in the ALDHhigh Sca-1+ cells. Another
interesting observation in our study was the significant
enrichment of MEF2C transcription factor exclusively in
the ALDHhigh Sca-1+ cells. MEF2C is known to be one of
the earliest markers of cardiac lineage [20], validating the
hypothesis that ALDHhigh Sca-1+ cells might represent a
primitive cardiac population in the fetal heart.
We observed higher expression of the proliferative
marker Ki67 and antiapoptotic transcript Bcl2 in ALDHhigh
Sca-1+ cells. Considering that primitive progenitor cells
typically possess high proliferative potential, this indicates
yet again that ALDHhigh Sca-1+ cells might represent the
transit amplifying cells in the fetal heart, which proliferate
extensively, and have robust prosurvival mechanisms, as
indicated by the Bcl2 levels. The role of Bcl2 in stem cell
survival and function has been extensively documented in
hematopoietic stem cells (HSCs) [21, 22], intestinal stem
cells [23], and melanocyte stem cells [24], to name a few.
It has been shown that Bcl2 increases both number and
self-renewal potential of HSCs by inhibiting their apoptosis
[21]. In a study of embryonic stem cell (ESC) transplantation
after cerebral ischemia in rats, overexpression of Bcl2 in the
ESCs increased survival of the transplanted cells and brought
about significant functional recovery in the brain [25]. In fact,
acetaldehyde-induced apoptosis was less in ALDHhigh Sca-1+
cells with respect to ALDHlow Sca-1+ cells.
Upon subsequent expansion, ALDHhigh Sca-1+ cells gave
rise to all population of cells including 28 to 40% of ALDHhigh
Sca-1+ cells and remaining ALDHlow Sca-1+ cells, thereby
recapitulating the original population; however ALDHlow
Sca-1+ cells primarily gave rise to ALDHlow Sca-1+ cells in
culture (<3.5% of ALDHhigh Sca-1+ cells). It was shown in case
of prostate stem cells that ALDHhigh cells proliferate much
more efficiently compared to ALDHlow cells [8].
In accordance with earlier studies, our observations
demonstrate that ALDHhigh Sca-1+ cells represent a primitive
stem/progenitor cell population in the human fetal heart.
Even though existence of ALDHhigh Sca-1+ cells in adult
human heart remains to be addressed, based on our findings,
we hypothesize that the adult heart also harbors an ALDHhigh
subpopulation, though their number might be much lower
than the fetal ones. It would therefore be interesting to
follow up this study in adult human heart samples and also
investigate if there is a change in the number or characteristics
of ALDHhigh Sca-1+ cells in pathological heart samples.
In recent years, bone marrow-derived ALDHhigh cells
were recruited to the area of ischemia within hours of
transplantation and continued accumulating for up to 1
week, increasing capillary formation in a hind limb ischemia
model [16]. ALDHhigh cell treatment enhanced the perfusion
ratio continuously even after 3 weeks compared to ALDHlow
cells [16]. In another study, human umbilical cord blood
(UCB) derived ALDHhigh cells with nanoparticle label were
injected into mice 24 hrs after induction of myocardial
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infarction. The ALDHhigh cells, but not the ALDHlow cells,
preferentially homed to and increased blood vessel formation
in the infarcted host myocardium [26]. These studies have
provided a strong basis for the clinical potential of ALDHhigh
cells in regenerative medicine. In fact, two clinical trials
were launched based on these studies [27, 28]. Therefore,
our current study of identifying and partially characterizing
ALDHhigh Sca-1+ progenitor cells in human fetal heart
is an important first step in moving forward to address
multiple questions, including differentiation studies of these
cells, understanding the role of different ALDH isozymes
in the function of Sca-1+ cells, and testing the therapeutic
potential of ALDHhigh progenitor cells in preclinical models
of cardiovascular diseases. More importantly, extrapolating
this approach to other types of cardiac progenitor cells such
as c-kit+ cells would be very useful for the advancement
of cardiac regenerative medicine. In conclusion, our study
reaffirms that high ALDH activity can be used as a functional
biochemical marker to isolate progenitor cells within the
heart, which possess enhanced self-renewal, proliferation,
and survival potential.
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